Chaoyang Liu1, Yixin Zhang1, Qing Liu1, Li Jiang1, Maolin Li1, Sha Wang2, Ting Long1, Wei He1, Xueying Kong1, Guangcheng Qin2, Lixue Chen2, Yuhong Zhang3, Jiying Zhou1. 1. 1 Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China. 2. 2 Laboratory Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China. 3. 3 The Clinical Molecular Diagnostics Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Abstract
Objective Previous studies of neuropathic pain have suggested that the P2X4 purinoceptor (P2X4R) in spinal microglia is essential for maintaining allodynia following nerve injury. However, little is known about its role in inflammatory soup-induced trigeminal allodynia, which closely mimics chronic migraine status. Here, we determined the contributions of P2X4R and related signaling pathways in an inflammatory soup-induced trigeminal allodynia model. Methods P2X4R gene and protein levels in the trigeminal nucleus caudalis were analyzed following repeated dural inflammatory soup infusions. p38, brain-derived neurotrophic factor, excitatory amino acid transporter 3, c-Fos, and calcitonin gene-related peptide protein levels in the trigeminal nucleus caudalis, as well as trigeminal sensitivity, were assessed among the different groups. Immunofluorescence staining was used to detect protein localization and expression in the trigeminal nucleus caudalis. Results Repeated inflammatory dural stimulation induced trigeminal hyperalgesia and the upregulation of P2X4R. Immunofluorescence revealed that P2X4R was expressed in trigeminal nucleus caudalis microglial cells. Blockage of P2X4R produced an anti-nociceptive effect, which was associated with an inhibition of inflammatory soup-induced increases in p38, brain-derived neurotrophic factor, excitatory amino acid transporter 3, c-Fos, and calcitonin gene-related peptide protein levels. The tyrosine receptor kinase B antagonist ANA-12 reversed trigeminal allodynia and the upregulation of excitatory amino acid transporter 3, c-Fos, and calcitonin gene-related peptide, whereas the agonist 7,8-dihydroxyflavone exacerbated these effects. Double immunostaining indicated that p38 and brain-derived neurotrophic factor were mainly expressed in microglial cells, whereas excitatory amino acid transporter 3 was primarily expressed in trigeminal nucleus caudalis neurons. Conclusions These data indicate that microglial P2X4R is involved in the regulation of excitatory amino acid transporter 3 via brain-derived neurotrophic factor-tyrosine receptor kinase B signaling following repeated inflammatory dural stimulation. Microglial P2X4R activation and microglia-neuron interactions in the trigeminal nucleus caudalis may play a role in the pathogenesis of migraine chronicity, and the modulation of P2X4R activation might be a potential therapeutic strategy.
Objective Previous studies of neuropathic pain have suggested that the P2X4 purinoceptor (P2X4R) in spinal microglia is essential for maintaining allodynia following nerve injury. However, little is known about its role in inflammatory soup-induced trigeminal allodynia, which closely mimics chronic migraine status. Here, we determined the contributions of P2X4R and related signaling pathways in an inflammatory soup-induced trigeminal allodynia model. Methods P2X4R gene and protein levels in the trigeminal nucleus caudalis were analyzed following repeated dural inflammatory soup infusions. p38, brain-derived neurotrophic factor, excitatory amino acid transporter 3, c-Fos, and calcitonin gene-related peptide protein levels in the trigeminal nucleus caudalis, as well as trigeminal sensitivity, were assessed among the different groups. Immunofluorescence staining was used to detect protein localization and expression in the trigeminal nucleus caudalis. Results Repeated inflammatory dural stimulation induced trigeminal hyperalgesia and the upregulation of P2X4R. Immunofluorescence revealed that P2X4R was expressed in trigeminal nucleus caudalis microglial cells. Blockage of P2X4R produced an anti-nociceptive effect, which was associated with an inhibition of inflammatory soup-induced increases in p38, brain-derived neurotrophic factor, excitatory amino acid transporter 3, c-Fos, and calcitonin gene-related peptide protein levels. The tyrosine receptor kinase B antagonist ANA-12 reversed trigeminal allodynia and the upregulation of excitatory amino acid transporter 3, c-Fos, and calcitonin gene-related peptide, whereas the agonist 7,8-dihydroxyflavone exacerbated these effects. Double immunostaining indicated that p38 and brain-derived neurotrophic factor were mainly expressed in microglial cells, whereas excitatory amino acid transporter 3 was primarily expressed in trigeminal nucleus caudalis neurons. Conclusions These data indicate that microglial P2X4Ris involved in the regulation of excitatory amino acid transporter 3 via brain-derived neurotrophic factor-tyrosine receptor kinase B signaling following repeated inflammatory dural stimulation. Microglial P2X4R activation and microglia-neuron interactions in the trigeminal nucleus caudalis may play a role in the pathogenesis of migraine chronicity, and the modulation of P2X4R activation might be a potential therapeutic strategy.
P2X4 purinoceptor (P2X4R) upregulation in spinal microglia is thought to be
involved in peripheral nerve injury-induced allodynia.[1] Recent work by Fried et al.,[2] studying blood–brain barrier (BBB) permeability, observed microglial
activation coupled with increased BBB permeability following repeated dural
inflammatory stimulation. However, the role of microglia, as well as P2X4R,
in the pathogenesis of inflammatory soup (IS)-induced trigeminal allodynia,
which closely mimics chronic migraine status, remains unclear.Following peripheral nerve injury (PNI), P2X4R activation promotes the
synthesis and release of brain-derived neurotrophic factor (BDNF) from
microglia through the activation of p38-mitogen-activated protein kinase
(p38-MAPK).[3,4] The interaction
between microglial P2X4R and neurons was further confirmed to be an
important link in neuropathic pain via BDNF-tyrosine receptor kinase B
(TrkB) signaling.[3-6]
Here, we investigated whether signaling between microglial P2X4R and neurons
is also an essential link in chronic migraine status and whether BDNF also
plays a crucial role in this process.The role of microglial P2X4R in regulating glutamate receptor activation and
GABAergic inputs has been thoroughly investigated in neuropathic
pain.[4,5,7,8] However, little evidence has been reported for
its role in modulating excitatory amino acid transporters (EAATs) in the
pathogenesis of neuropathic pain, as well as in migraine chronicity.
Sodium-dependent EAATs are divided into five subtypes, namely, EAAT1-5, of
which EAAT3 (EAAC1) is expressed in brain stem nuclei and is primarily
localized in neurons, with high levels observed at postsynaptic
sites.[9,10] Therefore, EAAT3 may reasonably play a larger
role in regulating regional glutamate (Glu) concentrations rather than
global concentrations, which are primarily regulated by glial EAAT1 (GLAST)
and EAAT2 (GLT-1) through recycling Glu into glutamine.[10,11]
Consistent with this hypothesis, recent studies demonstrated that a
selective EAAT3 inhibitor produced anti-nociceptive effects in rats
following periphery nerve injury, whereas EAAT1-2 inhibitors exacerbated
pain behaviors by increasing extracellular glutamate.[12] Accordingly, the effect of P2X4R on the regulation of EAAT3
expression and their potential relation to the development of trigeminal
allodynia were explored in this study.Previous studies have reported that expression of spinal EAATs is regulated by
neurotrophic factors through the activation of Trk receptors and
intracellular MAPK in neuropathic pain,[13] though the exact mechanism remains unclear. Recent work in a
depression model demonstrated that the regulation of glial GLT-1 via
BDNF-TrkB signaling was involved in the antidepressant effects of ketamine.[14] Therefore, the role of BDNF-TrkB signaling in the modulation of EAAT3
expression, as well as their possible effects on the development of
trigeminal allodynia, were studied here.To this end, we established an ISrat model of trigeminal allodynia, which
closely mimics chronic migraine status. In this rat model, repeated dural
stimulation with IS was administered to mimic repetitive dural nociceptor
activation and the clinical features of migraineurs.[15,16] In
the present study, we first examined the localization and expression changes
of P2X4R, p38, BDNF, and EAAT3. We then investigated whether EAAT3is
modulated by P2X4R through the administration of a P2X4R nonselective
inhibitor, TNP-ATP. Finally, we examined the role of BDNF in the regulatory
effect of P2X4R on EAAT3 using ANA-12 and 7,8-dihydroxyflavone (DHF), a
selective TrkB receptor antagonist and agonist, respectively. The protein
levels of calcitonin gene-related peptide (CGRP), a key neuropeptide
implicated in the activation of trigeminovascular system,[17-19]
and c-Fos, a commonly used marker of neuronal activation after pain
stimulation,[20-23] were also
analyzed.
Materials and methods
Animals
Adult male Sprague-Dawley rats (250–300 g, n = 87) were
used for the experiments. Rats were housed in a temperature- (23 ±
2°C) and humidity-controlled (50% ± 10%) room with ad libitum access
to water and food, under a 12-h light/dark cycle. All procedures
performed on the animals were approved by the Ethics Committee of the
Department of Medical Research at the First Affiliated Hospital of
Chongqing Medical University.
Experimental design
Rats were randomly assigned to seven different experimental groups, as
shown in Table
1. Two experiments were then conducted in rat models of
trigeminal allodynia induced by repeated dural IS infusions.
Table 1.
Schematic representation of experimental groups,
administration time (day, D), and sample size (number,
n) of rats per group.
Experimental group
D1–7
D8
RT-PCR (n)
WB (n)
IF (n)
Control (CON)
PBS
—
6
6
3
IS
IS
—
6
6
3
IS+PBS
IS
PBS
6
IS+TNP
IS
TNP-ATP (30 nmol)
6
3
IS
TNP-ATP (60 nmol)
6
IS+DMSO
IS
DMSO
6
IS+ANA
IS
ANA-12 (100 nmol)
6
3
IS
ANA-12 (200 nmol)
6
IS+DHF
IS
7,8-DHF (20 nmol)
6
3
IS
7,8-DHF (40 nmol)
6
RT-PCR: real-time polymerase chain reaction; WB:
western blot; IF: immunofluorescence; IS:
inflammatory soup; PBS: phosphate-buffered saline;
DHF: 7,8-dihydroxyflavone; DMSO:
dimethylsulfoxide.
Schematic representation of experimental groups,
administration time (day, D), and sample size (number,
n) of rats per group.RT-PCR: real-time polymerase chain reaction; WB:
western blot; IF: immunofluorescence; IS:
inflammatory soup; PBS: phosphate-buffered saline;
DHF: 7,8-dihydroxyflavone; DMSO:
dimethylsulfoxide.
Experiment 1
Rats in groups 1 to 4 were used to test the role of P2X4R and
related pathways in IS-induced allodynia and the regulation of
EAAT3. The P2X4R inhibitor 2′,3′-O-(2,4,6-trinitrophenyl)
adenosine 5′-triphosphate tetrasodium salt (TNP-ATP) was
dissolved in phosphate-buffered saline (PBS) and slowly
administered (5 μl/rat, intracerebroventricular injection
(i.c.v.)) across two doses using a microinfusion pump (WPI,
Sarasota, FL, USA) the next day after seven days of IS
infusions. The doses for TNP-ATP used in the experiment were
based on previous studies, which demonstrated clear inhibition
of P2X4R.[1,24] As a
control, rats in group 3 received the same volume of PBS (pH
7.4).Periorbital pressure thresholds were tested before IS or PBS
infusions and 1 h after drug treatment, after which the animals
were sacrificed. Following completion of the final threshold
tests, other post-treatment assessments included real-time
polymerase chain reaction (RT-PCR), western blotting, and
immunofluorescence (IF).
Experiment 2
Rats in groups 1, 2, and 5 to 7 were used to investigate the
underlying mechanisms by which P2X4R regulates the expression of
EAAT3. The TrkB receptor specific antagonist
N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-2-carboxamide
(ANA-12; 5 μl/rat, i.c.v.) or the agonist 7,8-DHF (5 μl/rat,
i.c.v.) were dissolved in dimethylsulfoxide and slowly
administered across two doses the next day after seven days of
IS infusions. The doses for ANA-12 and 7,8-DHF were based on
previous findings that reported reliable effects.[25-27] Rats in group 5 received the same
volume of dimethylsulfoxide as a control.Periorbital pressure thresholds were tested before IS or PBS
infusions and 1 h after drug treatment, after which the animals
were sacrificed. Following completion of the final threshold
tests, other post-treatment assessments included western
blotting and IF.
Craniotomy and cannula fixation
Surgical procedures were performed as described previously.[15,16] Rats were
fasted of food and water for 12 h before surgery to prevent abdominal
dilation. Under anesthesia with 10% chloral hydrate (4 ml/kg,
intraperitoneally), rats were placed in a stereotactic frame
(ST-51603; Stoelting Co., Chicago, IL, USA). Following local
infiltration anesthesia with lidocaine (0.1 g/5 ml), an incision was
made to expose the skull completely. A 1-mm diameter craniotomy (+1.5
mm from bregma, +1.5 mm lateral) was carefully performed using a burr
drill, avoiding any damage to the dura mater.[15] Next, a stainless-steel cannula with a plastic cap (Guide
Cannula for Rat, Item No.: 900–0062-001, O.D.: 0.64 mm; RWD Life
Science, Shenzhen, China) was placed just above the skull and fixed
with dental acrylic. Rats were allowed to recover for 1 week and then
randomly assigned for the subsequent experiments.
Infusion of IS or saline
Rats were placed in a transparent glass chamber (22 × 22 × 30 cm) that
allowed for free movement during infusion. The IS contained 1 mM each
of histamine, serotonin, bradykinin, and 0.1 mM prostaglandin E2 in
PBS, pH 7.4 (Sigma-Aldrich, St. Louis, MO, USA) (adapted from
Strassman et al.[28]). We steadily delivered 2 μl of IS or PBS over 5 min through a
microinfusion pump that was attached to the top of the cannula via a
polyethylene tube (PE50 Tubing, Item No.: 900–0062-301, 0.97 × 0.58
mm, RWD Life Science, Shenzhen, China). The same procedure was
repeated once daily for seven days (from Day 1 to Day 7, Table
1).
Tactile sensory testing
After a habituation period of 10 min in the chamber, rats were tested for
basal periorbital pressure thresholds prior to infusion and
periorbital pressure thresholds 1 h after drug treatment. Pressure
thresholds were determined by applying an electronic von Frey
monofilament (Electrovonfrey, model no.: 2391, IITC Inc., Woodland
Hills, CA, USA) to the periorbital region of the face over the rostral
portion of the eye, as reported by Oshinsky and Gomonchareonsiri.[29] The assigned force values of the von Frey device ranged from 0
to 800 g. The von Frey stimuli were gradually enhanced to determine
the response threshold. A positive response was suggested when the rat
stroked its face with the ipsilateral forepaw, quickly retracted its
head from the stimulus, or vocalized. The pressure thresholds were
recorded automatically and were determined three times at each site
with an interval of at least 1 min.
Quantitative RT-PCR
Rats were sacrificed under chloral hydrate anesthesia. The trigeminal
nucleus caudalis (TNC), 1 to 5 mm from the obex, according to the
atlas by Paxinos and Watson,[30] was rapidly separated and used for further analysis.[31] Total RNA was extracted from TNC segments using the RNAiso Plus
reagent (Takara) following the manufacturer’s instructions. Next, cDNA
was synthesized using the PrimeScript™ RT reagent kit (Takara, Tokyo,
Japan). RT-PCR was performed on a CFX96 Touch thermocycler (Bio-Rad)
using the SYBR® Premix Ex Taq™ II (Takara). The following specific
primers (Sangon Biotech, Shanghai, China) were used as follows:
P2X4R_forward: 5′-TCG TGT GGG AAA AGG GCT AC-3′, P2X4R_reverse: 5′-GTC
TGG TTC ACG GTG ACG AT-3′; GAPDH_forward: ATG ACT CTA CCC ACG GCA AGC
T-3′, GAPDH_reverse: 5′-GGA TGC AGG GAT GAT GTT CT-3′. Relative gene
expression was normalized to the internal reference GAPDH using the
2–ΔΔCTmethod.
Western blotting
Fresh tissue samples from TNC segments were homogenized in
radioimmunoprecipitation assay buffer containing a mixture of
proteinase inhibitors (Beyotime, China) and phosphatase inhibitors
(Boster, China) at 4°C for 1.5 h. Protein concentrations were
determined using the BCA protein assay kit (Beyotime, China). Protein
samples were separated via 10% sodium dodecyl sulfate-polyacrylamide
electrophoresis, and western blotting was performed using the
following antibodies: P2X4R (Abcam; 1:800), pp38 (Santa Cruz; 1:500),
p38 (Santa Cruz; 1:1000), BDNF (Santa Cruz; 1:300), EAAT3 (Bioss;
1:500), CGRP (Abcam; 1:2000), c-Fos (Santa Cruz; 1:500), and β-actin
(Proteintech; 1:5000) as a loading control.
IF staining
Rats were anesthetized with chloral hydrate and subjected to cardiac
perfusion with 200 ml of 0.9% saline, followed by 250 ml of 4%
paraformaldehyde in 0.1 M PBS. The areas from the medulla oblongata to
the first cervical cord were removed,[31,32] fixed overnight in 4% paraformaldehyde,
transferred to 30% sucrose in 0.1 M PBS until they sank to the bottom,
frozen, and then serially and transversely sectioned (10 μm thick)
through the segment of the TNC (approximately 1–5 mm from the obex,
Figure
1) on a cryostat (Leica). For immunostaining, sections were
rinsed three times in 0.1 M PBS before being incubated with 0.3%
Triton X-100 for 10 min and 10% normal goat serum for 30 min at 37°C.
Sections were incubated overnight at 4°C with primary antibodies
against P2X4R (rabbit polyclonal antibody, 1:800, Abcam), pp38 (mouse
monoclonal antibody; 1:100), BDNF (mouse monoclonal antibody; 1:100),
EAAT3 (rabbit polyclonal antibody, 1:500, Bioss), p-TrkB (mouse
monoclonal antibody; 1:100), CGRP (mouse monoclonal antibody, 1:500),
and c-Fos (mouse monoclonal antibody, 1:4000). Markers for microglia
(Iba-1; goat polyclonal antibody, 1:500, Abcam), astrocytes (glial
fibrillary acidic protein, mouse monopoly antibody, 1:100, Abcam), and
neurons (neuronal nuclei; mouse monoclonal antibody, 1:500, Abcam)
were used to identify the types of positive cells. After being rinsed
three times in PBS, sections were incubated overnight at 4°C with the
corresponding secondary antibodies: cy3-conjugated anti-goat IgG
(1:60, Proteintech), fluorescein isothiocyanate-conjugated anti-mouse
IgG (1:60, Proteintech), fluorescein isothiocyanate-conjugated
anti-rabbit IgG (1:60, Proteintech), or cy3-conjugated anti-rabbit IgG
(1:60, Proteintech). The sections were then incubated with
6′-diamidino-2-phenylindole staining solution (Beyotime, China) at
37°C for 8 min after being rinsed three times with PBS.
Negative-control sections were incubated with PBS instead of the
corresponding primary antibodies and showed no positive signals.
Sections were mounted and observed on a fluorescence microscope
(Leica). The number of P2X4R-, c-Fos-, and EAAT3-immunoreactive cells
in the TNC was measured using Image J software (version 1.8.0_112).
Three images randomly selected under high-power magnification (200×)
were obtained for TNC per sample.
Figure 1.
Schematic representation of the brain region for TNC. (a)
Side view of the rat brain to show the region of the TNC
for analysis. The brain region for TNC was analyzed along
the brainstem at approximately 1 to 5 mm from the obex.
(b) The coronal view shows the location of TNC in the rat
brain. (c) Immunofluorescence staining of coronal section
representing the brain region for TNC (Scale bar = 500
μm). (a) and (b) are adapted from George Paxinos and
Charles Watson.[30]
Schematic representation of the brain region for TNC. (a)
Side view of the rat brain to show the region of the TNC
for analysis. The brain region for TNC was analyzed along
the brainstem at approximately 1 to 5 mm from the obex.
(b) The coronal view shows the location of TNC in the rat
brain. (c) Immunofluorescence staining of coronal section
representing the brain region for TNC (Scale bar = 500
μm). (a) and (b) are adapted from George Paxinos and
Charles Watson.[30]
Statistical analysis
Data represent the mean ± standard error of the mean
(SEM). SPSS 20.0 was used for statistical
analysis. Differences between two groups were analyzed using the
independent samples T test. Differences in mechanical
thresholds were analyzed using two-way analysis of variance (ANOVA),
and differences among other variables were analyzed using one-way
ANOVA, both followed by a Tukey’s multiple comparison tests.
Differences were considered statistically significant at
P < 0.05.
Results
Decreased baseline mechanical thresholds following repeated dural
stimulation
To investigate changes in the mechanical threshold following repeated
dural IS infusions, we examined the baseline periorbital withdrawal
thresholds using a von Frey monofilament prior to daily infusion with
IS or PBS. Periorbital thresholds before infusions were not
significantly different between the two groups (two-way ANOVA,
P > 0.05; Figure 2(a)). However, the
periorbital threshold decreased significantly in the IS group compared
with the control group after the second infusion (two-way ANOVA,
P < 0.05; Figure 2(a)). In addition,
the periorbital thresholds reached a low level (∼3.0 g) after the
fifth IS infusion onto the dura, suggesting the establishment of
mechanical allodynia.
Figure 2.
Trigeminal sensitivity and P2X4R expression in the TNC
increase with repeated dural stimulation. (a) Decreased
baseline mechanical thresholds following repeated dural
stimulation with IS. The basal mechanical thresholds of
periorbital decreased in the IS group and were
significantly different from the PBS group after the
second infusion. (b) WB for P2X4R expression in the TNC
(upper panel) revealed that P2X4R protein level was
upregulated in the IS group compared with the CON group.
Quantification (lower panel) of WB experiments normalized
to actin control indicated an approximate twofold increase
in IS group. (c) RT-PCR for P2X4R in TNC revealed that
P2X4R mRNA level was significantly increased in the IS
group compared with the CON group. All data were
normalized to GAPDH controls. (e) Co-localization images
of P2X4R (green) with Iba-1 (red) in the TNC reveal
increased microglial activation and P2X4R expression in
the IS group compared with the CON group. Blue indicates
DAPI immunoreactivity, green indicates P2X4R
immunoreactivity, red indicates Iba-1 immunoreactivity,
and yellow indicates the merged signal. (d) Histogram
showed the statistical result of P2X4R expression in TNC
(e). Data represent the means ± SEM.
Statistical analyses in (a) were performed by two-way
ANOVA, followed by a Tukey test;
*P < 0.05,
***P < 0.001 (n = 12
per group). Statistical analyses in ((b), (c) and (d))
were performed by independent samples T
test; *P < 0.05,
**P < 0.01,
***P < 0.001 (n = 6
per group in (b) and (c); n = 3 per group
in (d)). Arrows indicate cells shown in the top right
corner of images at approximately 4X magnification. Scale
bar = 50 μm.
RT-PCR: real-time polymerase chain reaction; WB: western
blot; IS: inflammatory soup; PBS: phosphate-buffered
saline; CON: control.
Trigeminal sensitivity and P2X4R expression in the TNC
increase with repeated dural stimulation. (a) Decreased
baseline mechanical thresholds following repeated dural
stimulation with IS. The basal mechanical thresholds of
periorbital decreased in the IS group and were
significantly different from the PBS group after the
second infusion. (b) WB for P2X4R expression in the TNC
(upper panel) revealed that P2X4R protein level was
upregulated in the IS group compared with the CON group.
Quantification (lower panel) of WB experiments normalized
to actin control indicated an approximate twofold increase
in IS group. (c) RT-PCR for P2X4R in TNC revealed that
P2X4R mRNA level was significantly increased in the IS
group compared with the CON group. All data were
normalized to GAPDH controls. (e) Co-localization images
of P2X4R (green) with Iba-1 (red) in the TNC reveal
increased microglial activation and P2X4R expression in
the IS group compared with the CON group. Blue indicates
DAPI immunoreactivity, green indicates P2X4R
immunoreactivity, red indicates Iba-1 immunoreactivity,
and yellow indicates the merged signal. (d) Histogram
showed the statistical result of P2X4R expression in TNC
(e). Data represent the means ± SEM.
Statistical analyses in (a) were performed by two-way
ANOVA, followed by a Tukey test;
*P < 0.05,
***P < 0.001 (n = 12
per group). Statistical analyses in ((b), (c) and (d))
were performed by independent samples T
test; *P < 0.05,
**P < 0.01,
***P < 0.001 (n = 6
per group in (b) and (c); n = 3 per group
in (d)). Arrows indicate cells shown in the top right
corner of images at approximately 4X magnification. Scale
bar = 50 μm.RT-PCR: real-time polymerase chain reaction; WB: western
blot; IS: inflammatory soup; PBS: phosphate-buffered
saline; CON: control.
P2X4R expression and microglial activation increases with repeated
dural stimulation
P2X4R mRNA and protein levels in the TNC of rats were examined after
seven days of dural IS or PBS infusions. As shown in Figure 2(b) to
(d), P2X4R expression was significantly increased in the IS group
compared with the control (CON) group as found by RT-PCR (Independent
samples T test, P < 0.05; Figure 2(c)),
western blot (Independent samples T test, P <
0.001; Figure
2(b)), and IF (Independent samples T
test, P < 0.01; Figure 2(d) to (e)). IF
analysis revealed increased Iba-1 positive cells in TNC in the IS
group compared with the CON group (ANOVA, P <
0.01; Supplemental Figure 1). Moreover, P2X4R expression was present
in Iba-1-but not in glial fibrillary acidic protein-immunoreactive
cells (Figure
4(a) to (h)). These results suggested that microglial
activation and P2X4R expression were definitely increased in TNC
microglia in rats stimulated by repeated dural infusion of IS.
Figure 4.
Double immunostaining of P2X4R (b, f, green), p-p38 (j,
green), and BDNF (n, green) with Iba-1 (c, k, o, red), a
microglial marker, or GFAP (g, red), an astrocyte marker,
in the TNC of rats. (a) to (h) Immunofluorescence (IF) in
TNC from rats revealed that P2X4R is present in Iba-1-but
not in GFAP-immunoreactive cells (shown by arrows in a–h).
(i) to (p) Similar to P2X4R, IF in TNC revealed that p-p38
and BDNF staining were observed primarily in
Iba-1-positive cells (shown by arrows in i–p). Arrows
indicate cells shown in the top right corner of images at
approximately 4X magnification. Scale bar = 50 μm.
TNP-ATP treatment reverses trigeminal allodynia and microglial
activation following repeated dural stimulation
To study whether P2X4Ris relevant to the mechanical allodynia induced by
repeated dural stimulation, the P2X4R antagonist TNP-ATP was
administered the next day after the final IS infusion, and the
mechanical threshold was detected using electronic von Frey
monofilaments 1 h later. TNP-ATP administration significantly
increased the periorbital pressure threshold (ANOVA,
P < 0.001; Figure 3(g)). The IS+TNP-ATP
(30 nmol) and IS+TNP-ATP (60 nmol) groups did not differ significantly
(ANOVA, P > 0.05; Figure 3(g)). These results
suggest that the P2X4R antagonist TNP-ATP alleviated mechanical
allodynia in a concentration-independent manner, and the low-dose
group was therefore selected for the subsequent experiments. IF
analysis revealed that TNP-ATP (30 nmol) treatment reversed IS-induced
Iba-1 positive cells increase in TNC compared with the IS group
(ANOVA, P < 0.05; Supplemental Figure 1).
Figure 3.
P2X4R and related signaling pathways were involved in EAAT3
regulation and trigeminal allodynia following repeated
dural stimulation. (a) WB for p-p38 expression in the TNC
(upper panel) revealed that p-p38 protein level was
increased in the IS group compared with the CON group.
TNP-ATP (30 nmol) treatment repressed its expression as
compared to the group of IS+PBS. Quantification (lower
panel) of WB experiments was normalized to actin control.
(b) WB for p38 expression in the TNC (upper panel)
revealed no evident difference among the four groups.
Quantification (lower panel) of WB experiments was
normalized to actin control. (c) to (f): WB for BDNF (c),
CGRP (d), c-Fos (e), EAAT3 (f) expression in the TNC
(upper panel) revealed that BDNF, CGRP, c-Fos, and EAAT3
were all upregulated following repeated dural stimulation
as compared to control. TNP-ATP (30 nmol) treatment
decreased their protein levels compared with the group of
IS+PBS. There were no obvious difference between the group
of IS and IS +PBS. Quantification (lower panel) of all WB
experiments was normalized to actin control. (g) TNP-ATP
treatment significantly increased the basal periorbital
pressure thresholds compared with IS+PBS group. The
IS+TNP-ATP (30 nmol) and IS+TNP-ATP (60 nmol) groups
showed no obvious difference in anti-nociceptive effect.
(h) and (i): WB for P2X4R (h), p-p38 (i) expression in the
TNC (upper panel) revealed that ANA-12 (100 nmol)
treatment did not reverse IS-induced P2X4R and p-p38
upregulation. Quantification (lower panel) of WB
experiments was normalized to actin control. Data
represent the mean ± SEM. Statistical
analyses were performed by one-way ANOVA, followed by a
Tukey test; *P < 0.05,
**P < 0.01,
***P < 0.001 vs. CON,
#P < 0.05,
##P < 0.01,
###P < 0.001 vs.
IS+PBS (n = 6 per group).
P2X4R and related signaling pathways were involved in EAAT3
regulation and trigeminal allodynia following repeated
dural stimulation. (a) WB for p-p38 expression in the TNC
(upper panel) revealed that p-p38 protein level was
increased in the IS group compared with the CON group.
TNP-ATP (30 nmol) treatment repressed its expression as
compared to the group of IS+PBS. Quantification (lower
panel) of WB experiments was normalized to actin control.
(b) WB for p38 expression in the TNC (upper panel)
revealed no evident difference among the four groups.
Quantification (lower panel) of WB experiments was
normalized to actin control. (c) to (f): WB for BDNF (c),
CGRP (d), c-Fos (e), EAAT3 (f) expression in the TNC
(upper panel) revealed that BDNF, CGRP, c-Fos, and EAAT3
were all upregulated following repeated dural stimulation
as compared to control. TNP-ATP (30 nmol) treatment
decreased their protein levels compared with the group of
IS+PBS. There were no obvious difference between the group
of IS and IS +PBS. Quantification (lower panel) of all WB
experiments was normalized to actin control. (g) TNP-ATP
treatment significantly increased the basal periorbital
pressure thresholds compared with IS+PBS group. The
IS+TNP-ATP (30 nmol) and IS+TNP-ATP (60 nmol) groups
showed no obvious difference in anti-nociceptive effect.
(h) and (i): WB for P2X4R (h), p-p38 (i) expression in the
TNC (upper panel) revealed that ANA-12 (100 nmol)
treatment did not reverse IS-induced P2X4R and p-p38
upregulation. Quantification (lower panel) of WB
experiments was normalized to actin control. Data
represent the mean ± SEM. Statistical
analyses were performed by one-way ANOVA, followed by a
Tukey test; *P < 0.05,
**P < 0.01,
***P < 0.001 vs. CON,
#P < 0.05,
##P < 0.01,
###P < 0.001 vs.
IS+PBS (n = 6 per group).WB: western blot; IS: inflammatory soup; CON: control; PBS:
phosphate-buffered saline; BDNF: brain-derived
neurotrophic factor; CGRP: calcitonin gene-related
peptide; EAAT3: excitatory amino acid transporter 3.
P2X4R and related signaling pathways were involved in EAAT3
regulation and trigeminal allodynia following repeated dural
stimulation
The protein levels of p-p38, p38, and BDNF were detected in the TNC of
rats after seven days of dural IS stimulation and administration of
the P2X4R inhibitor TNP-ATP. The expression of p-p38 and BDNF were
strikingly upregulated following repeated dural stimulation, compared
with the CON group (ANOVA, P < 0.05; Figure 3(a) to
(c)). Moreover, TNP-ATP significantly suppressed p-p38 and BDNF
expression in the TNC of rats (ANOVA, P < 0.05;
Figure
3(a) to (c)). Because EAAT3is involved in the
glutamate-induced neuroplasticity underlying persistent pain,[12] we further examined the regulatory role of microglial P2X4R in
EAAT3, CGRP, and c-Fos expression. EAAT3, CGRP, and c-Fos expression
in the TNC segments of rats was significantly increased in the IS
group compared with the CON group (ANOVA, P <
0.05; Figure
3(d) to (f)). Furthermore, TNP-ATP administration reduced
EAAT3, CGRP, and c-Fos expression (ANOVA, P <
0.05; Figure
3(d) to (f)). Immunostaining revealed that p38 and BDNF
were primarily expressed in microglial cells (Figure 4(i) to (p)), while
EAAT3 was expressed in TNC neurons and activated microglial cells
(Figure
5(a) to (l)).
Figure 5.
Double immunostaining of EAAT3 (b, n, red; f, j, green) with
NeuN (c, green), GFAP (g, red), Iba-1 (k, red), and p-TrkB
(o, green) in the TNC of rats. (a) to (l)
Immunofluorescence (IF) in TNC of rats revealed that EAAT3
is present primarily in NeuN-positive cells (shown by
arrows in a-d). There was relatively less expression in
Iba-1-positive cells (i) to (l), and expression in
GFAP-positive neurons was not detected (e) to (h). (m) to
(p) IF in TNC of rats revealed that EAAT3 (n) and TrkB (o)
co-expressed (yellow, p). Arrows indicate cells shown in
the top right corner of images (d, h, l, p) at
approximately 4X magnification. Scale bar = 50 μm.
Double immunostaining of P2X4R (b, f, green), p-p38 (j,
green), and BDNF (n, green) with Iba-1 (c, k, o, red), a
microglial marker, or GFAP (g, red), an astrocyte marker,
in the TNC of rats. (a) to (h) Immunofluorescence (IF) in
TNC from rats revealed that P2X4Ris present in Iba-1-but
not in GFAP-immunoreactive cells (shown by arrows in a–h).
(i) to (p) Similar to P2X4R, IF in TNC revealed that p-p38
and BDNF staining were observed primarily in
Iba-1-positive cells (shown by arrows in i–p). Arrows
indicate cells shown in the top right corner of images at
approximately 4X magnification. Scale bar = 50 μm.BDNF: brain-derived neurotrophic factor; DAPI:
6′-diamidino-2-phenylindole; P2X4R: P2X4 purinoceptor;
GFAP: glial fibrillary acidic protein.Double immunostaining of EAAT3 (b, n, red; f, j, green) with
NeuN (c, green), GFAP (g, red), Iba-1 (k, red), and p-TrkB
(o, green) in the TNC of rats. (a) to (l)
Immunofluorescence (IF) in TNC of rats revealed that EAAT3is present primarily in NeuN-positive cells (shown by
arrows in a-d). There was relatively less expression in
Iba-1-positive cells (i) to (l), and expression in
GFAP-positive neurons was not detected (e) to (h). (m) to
(p) IF in TNC of rats revealed that EAAT3 (n) and TrkB (o)
co-expressed (yellow, p). Arrows indicate cells shown in
the top right corner of images (d, h, l, p) at
approximately 4X magnification. Scale bar = 50 μm.DAPI: 6′-diamidino-2-phenylindole; EAAT3: excitatory amino
acid transporter 3; GFAP: glial fibrillary acidic protein;
TrkB: tyrosine receptor kinase B.To further verify the establishment of the signaling cascade from P2X4R
activation to BDNF release, we examined the effect of ANA-12 on P2X4R
and p-p38 expression in TNC. ANA-12 treatment did not cause obvious
changes in protein expression of P2X4R as well as p-p38 (ANOVA,
P > 0.05; Figure 3(h) and (i)). The
effect of TNP-ATP on trigeminal allodynia and p-p38, BDNF, CGRP,
c-Fos, and EAAT3 expression in CON rats were also examined. Results
showed that TNP-ATP (30 nmol) did not cause significant changes in the
periorbital threshold or p-p38, BDNF, CGRP, c-Fos, and EAAT3
expression as compared to the group of CON+PBS (ANOVA,
P > 0.05; Supplemental Figure 2(a) to
(f)).
BDNF-TrkB pathways were involved in trigeminal allodynia and EAAT3
regulation following repeated dural stimulation
To further study whether BDNFis closely related to the mechanical
allodynia induced by repeated IS stimulation, the TrkB antagonist
ANA-12 and agonist 7,8-DHF were administered the next day after seven
times of IS infusions. Electronic von Frey monofilaments were applied
to test the mechanical threshold 1 h after drug intervention.
Periorbital thresholds were markedly increased after ANA-12
administration and significantly decreased following 7,8-DHF
administration (ANOVA, P < 0.05; Figure 6(a)).
The low-dose and high-dose groups did not differ significantly,
suggesting that ANA-12 treatment reverses mechanical allodynia by
blocking the action of BDNF, whereas 7,8-DHF exacerbates this effect,
in a concentration-independent manner. Therefore, the low-dose groups
were selected for the subsequent experiments.
Figure 6.
BDNF-TrkB pathways were involved in trigeminal allodynia and
EAAT3 regulation following repeated dural stimulation. (a)
ANA-12 treatment significantly increased the basal
periorbital thresholds, while 7,8-DHF further reduce the
thresholds as compared to the group of IS+DMSO. The
low-dose and high-dose groups of ANA-12 as well as 7,8-DNF
did not differ significantly. (b) to (d): WB for CGRP (b),
c-Fos (c), and EAAT3 (d) expression in the TNC (upper
panel) revealed that CGRP, c-Fos, and EAAT3 protein levels
were all increased following repeated dural stimulation as
compared to control. ANA-12 (100 nmol) treatment decreased
their expression, while 7,8-DHF (20 nmol) caused a further
increase compared with the group of IS+DMSO. There were no
obvious difference between the group of IS and IS +DMSO.
Quantification (lower panel) of all WB experiments was
normalized to actin control. (g) Representative
immunofluorescence samples of c-Fos and EAAT3 in the TNC
in the CON, IS, IS+ANA (100 nmol), and IS+DHF (20 nmol)
groups. Scale bar = 50 μm. (e) and (f) Histograms showed
the statistical results of c-Fos and EAAT3 expression in
TNC (g). Data represent the mean ± SEM.
Statistical analyses were performed by one-way ANOVA,
followed by a Tukey test; *P < 0.05,
**P < 0.01,
***P < 0.001 vs. CON,
#P < 0.05,
##P < 0.01,
###P < 0.001 vs. IS
or IS+DMSO (n = 6 per group in a ∼ d;
n = 3 per group in e and f).
BDNF-TrkB pathways were involved in trigeminal allodynia and
EAAT3 regulation following repeated dural stimulation. (a)
ANA-12 treatment significantly increased the basal
periorbital thresholds, while 7,8-DHF further reduce the
thresholds as compared to the group of IS+DMSO. The
low-dose and high-dose groups of ANA-12 as well as 7,8-DNF
did not differ significantly. (b) to (d): WB for CGRP (b),
c-Fos (c), and EAAT3 (d) expression in the TNC (upper
panel) revealed that CGRP, c-Fos, and EAAT3 protein levels
were all increased following repeated dural stimulation as
compared to control. ANA-12 (100 nmol) treatment decreased
their expression, while 7,8-DHF (20 nmol) caused a further
increase compared with the group of IS+DMSO. There were no
obvious difference between the group of IS and IS +DMSO.
Quantification (lower panel) of all WB experiments was
normalized to actin control. (g) Representative
immunofluorescence samples of c-Fos and EAAT3 in the TNC
in the CON, IS, IS+ANA (100 nmol), and IS+DHF (20 nmol)
groups. Scale bar = 50 μm. (e) and (f) Histograms showed
the statistical results of c-Fos and EAAT3 expression in
TNC (g). Data represent the mean ± SEM.
Statistical analyses were performed by one-way ANOVA,
followed by a Tukey test; *P < 0.05,
**P < 0.01,
***P < 0.001 vs. CON,
#P < 0.05,
##P < 0.01,
###P < 0.001 vs. IS
or IS+DMSO (n = 6 per group in a ∼ d;
n = 3 per group in e and f).IS: inflammatory soup; CON: control; DMSO: dimethylsulfoxide;
DHF: 7,8-dihydroxyflavone; CGRP: calcitonin gene-related
peptide; EAAT3: excitatory amino acid transporter 3.Although previous studies have indicated that EAAT3 expression is
regulated by neurotrophic factors, the underlying mechanisms remain
unclear. We further investigated the regulatory effects of BDNF on
EAAT3, CGRP, and c-Fos expression. The TrkB antagonist ANA-12
significantly reduced EAAT3, CGRP, and c-Fos expression in the TNC
compared with the IS group (ANOVA, P < 0.05; Figure 6(b) to
(g)). Whereas administration of the TrkB agonist 7,8-DHF further
elevated EAAT3, CGRP, and c-Fos expression (ANOVA, P
< 0.05; Figure
6(b) to (g), the typical IF samples for c-Fos and EAAT3
were showed in Figure
6(g)).The effect of ANA-12 and 7,8-DHF on trigeminal allodynia and CGRP, c-Fos,
and EAAT3 expression in CON rats were also examined. Results showed
that ANA-12 (100 nmol) did not cause significant changes in the
periorbital threshold or CGRP, c-Fos, and EAAT3 expression as compared
to the group of CON+PBS (ANOVA, P > 0.05;
Supplemental Figure 2(a, d–f)). 7,8-DHF (20 nmol) treatment evidently
decreased the thresholds while increased the expression of CGRP,
c-Fos, and EAAT3 as compared to the group of CON+PBS (ANOVA,
P < 0.05; Supplemental Figure 2(a,
d–f)).
Discussion
Previous studies of neuropathic pain have reported that P2X4R in spinal
microglia is crucial for maintaining PNI-induced allodynia.[1,4,6] The
present study reveals a potential role for microglial P2X4R in the
regulation of EAAT3 in the ISrat model of trigeminal allodynia.
Specifically, the activation of microglial P2X4R may cause p38 activation
and eventually promote EAAT3 expression via BDNF-TrkB signaling following
repeated dural inflammatory stimulation. Therefore, microglial activation
may play a role in the pathogenesis of migraine chronicity.Repeated infusion of IS onto the dura is a commonly used rat model of migraine.[15] Chemical stimulation of the dura is believed to activate the
trigeminovascular system and lead to trigeminal allodynia that is
similar to the common symptoms observed in migraineurs.[28] In the present study, periorbital thresholds decreased
significantly following the second IS infusion and reached to a low
level (∼3.0 g) after the fifth infusion, suggesting the progression to
trigeminal allodynia. Recent reports have focused on two widely used
migraine model induced by repeated dural stimulation with
IS.[15,29] One model involves seven successive days of
dural IS infusions.[15,16] as described in the present study. This model
mimics several clinical features displayed by migraineurs, such as
decreased basal thresholds, decreased routine physical activity,
increased resting behavior, and the pharmacological effectiveness of
migraine treatment.[15,16] In the other model, rats are infused with IS
onto the dura, and the same procedure is repeated three times per week
for up to 4 weeks.[2,29] Repeated infusions of IS in the two animal
models both induce a lasting decrease (low threshold state) in
periorbital basal pressure thresholds. Therefore, repeated dural
stimulation with IS may produce a chronic state of trigeminal
activation and may therefore be suitable for elucidating the potential
mechanisms underlying chronic migraine status.
P2X4R expression and microglial activation increase with repeated
dural stimulation
Previous evidence of microglial activation in migraine model was provided
by a study of BBB permeability, in which microglial activation was
detected along with increased BBB permeability following repeated
dural inflammatory stimulation.[2] In line with this study, our experiments demonstrated that
repetitive IS application increased the number of Iba-1 positive cells
in TNC which could be reversed by TNP-ATP treatment. Microglial P2X4Ris known to play an essential role in the chronic pain conditions
gating PNI and morphine-induced hyperalgesia.[1,8] Our findings
revealed that repeated dural stimulation induced a strong upregulation
of P2X4R in the TNC, compared with only low expression in control
animals. We also observed that the induction of P2X4R expression in
the TNC following repeated dural stimulation was confined to
microglia. Thus, increased P2X4R expression in activated TNC microglia
might be involved in chronic migraine.
P2X4R and related pathways were involved in trigeminal allodynia and
EAAT3 regulation following repeated dural stimulation
The interaction between microglial P2X4R and neurons has been confirmed
to be a vital link in neuropathic pain, and p38-BDNFis a crucial
signaling pathway involved in this process.[3-6] In the present
study, our results demonstrated that pp38 and BDNF expression in the
TNC was markedly increased following repeated dural stimulation, while
TNP-ATP treatment prevented p38-BDNF signaling, as well as trigeminal
allodynia. Our results also indicated that p38 and BDNF were expressed
in TNC microglia. Although the sources of p38 and BDNF elucidated here
are not in complete agreement with the findings reported for
neuropathic pain.[3,5] p38-BDNF signaling regulated by microglial P2X4Ris nevertheless likely implicated in chronic migraine.BDNF from P2X4R-positive microglia plays an important role in PNI and
morphine-induced hyperalgesia by regulating the activity of the NMDA
receptor[4,7] and downregulating the potassium-chloride
cotransporter KCC2 in dorsal horn neurons.[5,8,33] Yet the role
of microglial P2X4R in regulating EAATs in the pathogenesis of
migraine chronicity, as well as in neuropathic pain, remains to be
completely clarified. Five subtypes of EAATs have been determined to
date, of which EAAT1-2 are primarily observed in glial cells and play
an essential role in extracellular glutamate homeostasis in the
central nervous system.[34] EAAT3is primarily expressed in neurons, with high expression
at postsynaptic sites[9,10] that is believed to primarily modulate regional
Glu concentrations.[10,11] Since the role of EAAT4 and EAAT5 are still
unclear, we investigated only neuronal EAAT3 in the present study.
EAAT3 was primarily expressed in TNC neurons, consistent with previous findings.[9] Moreover, our results demonstrated that EAAT3 was partially
expressed in TNC microglia. Although most studies demonstrate that
EAAT3is neuronal, several groups have reported EAAT3 expression in
glial cells.[34,35] These
studies found that EAAT3 gene and protein expression increased with
microglial activation.[35] Our results suggested the involvement of microglial P2X4R in
the regulation of EAAT3 in TNC, whereby blocking P2X4R prevented the
upregulation of EAAT3 induced by repeated dural stimulation.Similar to our findings, Kerui GongM demonstrated that sustained
administration of morphine for seven days resulted in hyperalgesia and
upregulated EAAT3 in dorsal root ganglia neurons.[36] Previous studies of neuropathic pain also reported that spinal
EAAT3 exhibits a biphasic change following chronic constriction nerve
injury (CCI), with an initial upregulation followed by
downregulation.[13,37] An explanation for EAAT3 downregulation may be
that CCI results in degenerative changes in primary afferents.[13] The time course of the late phase downregulation was thought to
resemble changes in spinal CGRP and substance P expression following CCI.[38] No loss of trigeminal nerve primary afferents has been reported
in studies of chronic migraine. The upregulation of EAAT3, which may
be different from the changes of glial EAAT1-2, can thus be reasonably
concluded to participate in the pathogenesis of migraine
chronicity.A previous study using intrathecal injections of K252a, a nonselective
inhibitor for Trk receptors, reported that spinal EAATs were regulated
by neurotrophic factors via Trk receptor activation following PNI.[13] Trk receptors include subtypes TrkA, TrkB, and TrkC, which are
activated by nerve growth factor, BDNF, and neurotrophin-3, respectively.[13] Serum levels of neurotrophic factors, specifically BDNF, are
increased during migraine attacks compared with headache-free
intervals.[39,40] BDNFis thought to exert a crucial role in pain
modulation and central sensitization after acting on its
receptor.[5,7,24,44,45] Activation
of Trk receptors then initiates downstream cascades, including MAPK
activation, to promote the expression of several proteins.[41,42] Recently,
GLT-1 expression in astrocytes was found to be regulated by BDNF-TrkB
signaling in a rat model of depression.[14] Our findings demonstrated that BDNF-TrkB signaling is involved
in the development of trigeminal allodynia and the modulation of
EAAT3, given that TrkB inhibitor treatment remarkably prevented the
mechanical allodynia and the expression of EAAT3. Similar to our
results, the work by Burgos-Vega et al.[43] also showed a role for BDNF using ANA-12 and TrkB-Fc in
behavioral responses following dural stimulation.Recent studies of neuropathic pain showed that sex differences exist in
the pathological mechanism of pain between males and
females.[44,45] They found that the involvement of spinal
microglial BDNF in the induction of mechanical allodynia after nerve
injury was male specific.[44] This is the limitation of the present study that female rats
did not contain in the study yet migraine occurs predominantly in
female humans. So, female animals should be included in future studies
to evaluate the sex differences in the pathogenesis of migraine in
order to extract conclusions relevant to female patients.In summary, our results suggest a potential role for microglial P2X4R in
an IS-induced trigeminal allodynia model that regulates EAAT3
expression via BDNF-TrkB signaling, as shown in Figure 7. Repeated dural
inflammatory stimulation induces the activation of TNC microglial
cells and a prominent increase in P2X4R expression. The activation of
P2X4R in the brain regions which including TNC is essential for
trigeminal allodynia following repeated dural IS infusions.
Pharmacological blockade of P2X4R evidently prevents trigeminal
allodynia, suggesting that IS-induced trigeminal allodynia depends on
the activation of microglial P2X4R and related signaling pathways.
Furthermore, the activation of microglial P2X4R and BDNF-TrkB
signaling increased EAAT3 expression, which may further cause the
activation of the intracellular metabotropic glutamate 5 receptor
(mGluR5) by transporting glutamate into the cell, as shown in a recent
study of neuropathic pain.[12] Accumulating evidence suggests that mGluR5is a crucial
mediator of glutamate-induced neuroplasticity underlying persistent
pain.[46-50] Since blocking P2X4 or TrkB receptors prevents
the upregulation of EAAT3 and trigeminal allodynia, pharmacological
blockade of these receptors may represent a potential therapeutic
approach for treating trigeminal allodynia, as seen in migraineurs.
More studies are needed to further investigate the precise mechanisms
underlying microglia-neuron interactions in the pathophysiology of
chronic migraine.
Figure 7.
Schematic representation of the potential mechanisms by which
the P2X4 receptor in activated microglia modulates EAAT3
expression in the TNC in an IS-induced trigeminal
allodynia model. Following repeated dural inflammatory
stimulation, P2X4R expression is elevated in TNC
microglia. Upregulation of microglial P2X4R promotes the
activation of p38-MAPK and the synthesis and release of
BDNF. By acting on its high-affinity receptor, TrkB, BDNF
upregulates the glutamate transporter EAAT3. Glutamate
influx through EAAT3 may further activate intracellular
metabotropic glutamate 5 receptor (mGluR5), which is
essential for enhanced Ca2+-dependent Fos and
plays a crucial role in the glutamate-induced
neuroplasticity underlying persistent pain.[12,46–50]
Schematic representation of the potential mechanisms by which
the P2X4 receptor in activated microglia modulates EAAT3
expression in the TNC in an IS-induced trigeminal
allodynia model. Following repeated dural inflammatory
stimulation, P2X4R expression is elevated in TNC
microglia. Upregulation of microglial P2X4R promotes the
activation of p38-MAPK and the synthesis and release of
BDNF. By acting on its high-affinity receptor, TrkB, BDNF
upregulates the glutamate transporter EAAT3. Glutamate
influx through EAAT3 may further activate intracellular
metabotropic glutamate 5 receptor (mGluR5), which is
essential for enhanced Ca2+-dependent Fos and
plays a crucial role in the glutamate-induced
neuroplasticity underlying persistent pain.[12,46-50]EAAT3: excitatory amino acid transporter 3; TrkB: tyrosine
receptor kinase B; P2X4R: P2X4 purinoceptor; BDNF:
brain-derived neurotrophic factor.Click here for additional data file.Supplemental material, Supplemental Figures for P2X4-receptor
participates in EAAT3 regulation via BDNF-TrkB signaling in a model of
trigeminal allodynia by Chaoyang Liu, Yixin Zhang, Qing Liu, Li Jiang,
Maolin Li, Sha Wang, Ting Long, Wei He, Xueying Kong, Guangcheng Qin,
Lixue Chen, Yuhong Zhang and Jiying Zhou in Molecular Pain
Authors: Michael E Hildebrand; Jian Xu; Annemarie Dedek; Yi Li; Ameet S Sengar; Simon Beggs; Paul J Lombroso; Michael W Salter Journal: Cell Rep Date: 2016-12-06 Impact factor: 9.423
Authors: E Knyihár-Csillik; J Toldi; A Mihály; B Krisztin-Péva; Z Chadaide; H Németh; R Fenyo; L Vécsei Journal: J Neural Transm (Vienna) Date: 2006-08-10 Impact factor: 3.575
Authors: Carolyn A Purgert; Yukitoshi Izumi; Yuh-Jiin I Jong; Vikas Kumar; Charles F Zorumski; Karen L O'Malley Journal: J Neurosci Date: 2014-03-26 Impact factor: 6.167
Authors: Marco Túlio A Tanure; Rodrigo S Gomez; Rubens Carlos L Hurtado; Antônio L Teixeira; Renan Barros Domingues Journal: J Headache Pain Date: 2010-06-17 Impact factor: 7.277